A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants

Genentech

Status and phase: Completed; Phase 1

Conditions: Healthy Participants

Treatments: Drug: Rosuvastatin; Drug: Digoxin; Drug: Divarasib

Study type: Interventional

Funder types: Industry

Identifiers

NCT06677957

GP45712

Details and patient eligibility

About

This is a Phase 1, open-label, two-period, one-sequence, crossover drug-drug interaction study to assess the P-gp and BCRP inhibition potential of divarasib using digoxin and rosuvastatin as probe substrates, respectively, in healthy participants.

Enrollment: 19 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males or females of non-childbearing potential
• Within body mass index (BMI) range of 18.0 to 32.0 kg/m2, inclusive

Exclusion criteria

• Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator
• Poor peripheral venous access

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

19 participants in 2 patient groups

Treatment A

Experimental group

Description:

Participants will receive a single oral dose of Digoxin and Rosuvastatin drug cocktail.

Treatment:

Drug: Digoxin

Drug: Rosuvastatin

Treatment B

Experimental group

Description:

Participants will receive a single dose of Digoxin and Rosuvastatin drug cocktail administered 2 hours after the Divarasib dose on Day 5.

Treatment:

Drug: Divarasib

Drug: Digoxin

Drug: Rosuvastatin